ReviewInternational urology and nephrology2025
Autologous platelet-rich plasma therapy for skin ulceration due to calcific uremic arteriopathy: a case report and review of the literature.
Review in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionCalcific uremic arteriolopathy (CUA) is a rare, but severe complication primarily affecting end-stage kidney disease (ESKD) patients on dialysis. It is characterized by calcification of small and medium-sized blood vessels, leading to ischemia and the development of painful, non-healing cutaneous ulcers. Although platelet-rich plasma (PRP), which is enriched with growth factors, has shown efficacy in treating various chronic ulcers, its use in CUA-related wounds remains poorly documented.
objectiveThis case report describes the novel application of PRP therapy in managing CUA-associated skin ulcers in an ESKD patient. The aim of this study was to evaluate the safety of this treatment and document preliminary clinical outcomes. CASE REPORT: A patient with ESKD and CUA-related non-healing skin ulcers, who showed no improvement despite medical management for secondary hyperparathyroidism, hyperphosphatemia, and hypercalcemia, experienced progressive wound healing following autologous PRP therapy. The PRP was prepared using a two-step centrifugation process and applied topically after wound debridement. Over five PRP treatment sessions at 5-day intervals within 25 days, the patient achieved complete wound closure (100% reduction from 1.5 to 0 cm
conclusionAs an autologous product, PRP demonstrated complete wound resolution in this dialysis patient with CUA-associated refractory ulcers that were unresponsive to conventional therapies. These findings suggest that PRP may be considered as an adjunct therapy for calcific arteriolopathy, though further validation through controlled clinical trials is warranted.
Indexed as
Identifiers
40220119What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.